Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6116492 | 0.86 | MEN1 (0.48) | POLBSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL6115727 | 0.80 | P2RY12 (0.45) | SMN1; SMN2LMNA | |
| SCHEMBL6117360 | 0.78 | P2RY12 (0.43) | POLBSMN1; SMN2LMNA | |
| SCHEMBL4038440 | 0.78 | NR4A2 (0.49) | SMN1; SMN2LMNANR4A2MAPTGAA | |
| SCHEMBL8738758 | 0.74 | S1PR1 (0.47) | LMNAALDH1A1TP53 | |
| SCHEMBL8358799 | 0.73 | NR4A2 (0.53) | LMNAALDH1A1NR4A2MAPTGAA | |
| SCHEMBL18284180 | 0.73 | IDO1 (0.49) | LMNANR4A2GAA | |
| SCHEMBL8356414 | 0.72 | LMNA (0.70) | LMNAALDH1A1NR4A2SERPINE1 | |
| SCHEMBL7524478 | 0.72 | DYRK1A (0.46) | SMN1; SMN2LMNANR4A2MAPTGAA | |
| SCHEMBL2430574 | 0.70 | NR4A2 (0.72) | LMNAALDH1A1NR4A2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530462-B2 | Indole modulators of S1P receptors | ALLERGAN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530462-B2 | Indole modulators of S1P receptors | ALLERGAN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| WO-2012071184-A1 | INDOLE DERIVATIVES AS MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120129829-A1 | NOVEL INDOLE MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129829-A1 | NOVEL INDOLE MODULATORS OF S1P RECEPTORS | ALLERGAN, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129829-A1 | NOVEL INDOLE MODULATORS OF S1P RECEPTORS | S1PR1, S1PR3, S1PR2 | POLB 4822/4885SMN1; SMN2 4319/4885LMNA 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.